Returning to HIV Care with Biktarvy
Part of Immune system & allergy, Infections clinical trials.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have HIV-1, confirmed by a test showing the virus or its markers.
- You previously took HIV medication for at least 30 days in a row.
- You have not taken any HIV medication (pills or shots) for at least 12 weeks.
- You are ready and interested in restarting HIV treatment.
- You weigh at least 55 pounds (25 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
This trial tests switching back to a single-pill HIV treatment (B/F/TAF) for people who stopped a different type of HIV medicine (called an NNRTI) at least 90 days ago. It aims to see if restarting the same day is safe and works well.
This study measures the “hidden” HIV reservoir in the body and how it relates to blood levels of antiretroviral medicines. It may help doctors better understand why HIV can remain even when the virus is controlled.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.